HMGCR
ENSG00000113161
Target class
Enzyme
Chromosome
5
Approved drugs
10
Clinical candidates (approved and in development)
10
- Approved drugs
- 10
- ClinGen gene-disease validity
- Moderate
- Clinical candidates (approved and in development)
- 10
- Chemical probe available
- Yes
- Target name
- HMGCR
- Gene name
- 3-hydroxy-3-methylglutaryl-CoA reductase
- Gene symbol
- HMGCR
- Protein name
- 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase) (EC 1.1.1.34)
- Gene biotype
- Protein coding
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 54
- Highest tissue expression
- 80.4
- Tissue specificity (Gini)
- 0.393
- Tissue specificity (tau)
- 0.771
- KEGG gene identifiers
- hsa:3156
- Reactome pathways
- R-HSA-9619665
- Protein interaction confidence
- 0.8547
- Protein interaction partners
- 70
- End position
- 75364241
- Start position
- 75336329
- Chromosome
- 5
- Strand
- Forward
- Endoplasmic reticulum membrane
- Multi-pass membrane protein . Peroxisome membrane
- Multi-pass membrane protein .
- PubMed 17180682
- PubMed 2991281
- Tissue specificity (tau)
- 0.770823
- Expression inequality (Gini)
- 0.392831
Expression in transcripts per million
- Skin - Not Sun Exposed (Suprapubic)
- 80.4
- Skin - Sun Exposed (Lower leg)
- 73.77
- Cells - EBV-transformed lymphocytes
- 66.15
- Esophagus - Mucosa
- 63.81
- Vagina
- 42.86
Expression in transcripts per million
- Skin - Not Sun Exposed (Suprapubic)80.4
- Skin - Sun Exposed (Lower leg)73.77
- Cells - EBV-transformed lymphocytes66.15
- Esophagus - Mucosa63.81
- Vagina42.86
- Adrenal Gland42.44
- Brain - Cerebellar Hemisphere31.92
- Brain - Frontal Cortex (BA9)28.76
- Testis26.34
- Brain - Cerebellum26.17
- Cells - Cultured fibroblasts25.65
- Colon - Transverse23.38
- Lung22.73
- Nerve - Tibial20.24
- Thyroid20.17
- Small Intestine - Terminal Ileum20.05
- Brain - Spinal cord (cervical c-1)19.86
- Brain - Cortex19.83
- Brain - Hypothalamus19.62
- Brain - Anterior cingulate cortex (BA24)17.41
- Cervix - Endocervix16.33
- Spleen16.05
- Minor Salivary Gland15.77
- Brain - Nucleus accumbens (basal ganglia)15.68
- Pituitary15.07
And 29 more, listed on the interactive page.
Biological processes
- GO:0006695
- GO:0005778
- GO:0005783
- GO:0005789
- GO:0004420
- GO:0005515
- GO:0070402
- GO:0120225
Decrease, Fertility
Effects
- Inhibition/Decrease/Downregulation
Studies
- cell-based
Evidence source
Related records
Trials (2,299)
- "Efficacy Of 1.2% Rosuvastatin Gel In The Management Of Infrabony Defects"
- [Effects of Selected Statins on Cardiovascular Parameters in Healthy Volunteers]
- 1.2% Atorvastatin and 1.2% Simvastatin in Treatment of Chronic Periodontitis
- 1.2% Rosuvastatin Gel As A Local Agent In Smokers With Chronic Periodontitis
- 1.2% Rosuvastatin Subgingivally Delivered In Chronic Periodontitis With Type 2 Diabetes Mellitus
- 12-week Open-label, Phase IIIb Comparing Efficacy and Safety of Rosuvastatin (CRESTOR™) in Combination With Ezetimibe
- 15-Day Repeated-Dose Study With SB-649868 And Its Interaction With CYP3A4 Isoenzyme In Healthy Male Subjects.
- 30 Week Study of the Combination of ABT-335 and Rosuvastatin Compared to Rosuvastatin Monotherapy for Subjects With Dyslipidemia and Stage 3 Chronic Kidney Disease
- 3Mixtatin Versus Modified 3Mix-MP in Lesion Sterilization and Tissue Repair for Treatment of Necrotic Primary Molars
- 48-wk Open Label Phase IIIb to Evaluate Efficacy and Safety
- 7 Tesla MRI Study in Patients With Statin Related Muscle Complaints
- 7-day Atorvastatin and Emotional Processing
- 7-day Simvastatin and Emotional Processing
- 7T Magnetic Resonance Spectroscopy and Skeletal Muscle Biopsy Findings in Statin Associated Adverse Muscle Events
- 8-Week PK/PD Atorvastatin Study In Children And Adolescents With Heterozygous Familial Hypercholesterolemia
- A 10-12 Week Study to Evaluate the Safety and Efficacy of 320 mg Valsartan and 80 mg Simvastatin in Combination and as Monotherapies in Treating Hypertension and Hypercholesterolemia
- A 12 Week Study of MK0653A in Patients Who Have Been Hospitalized for a Possible Heart Problem (0653A-808)
- A 12-Week Study Comparing Pitavastatin 4 mg vs. Pravastatin 40 mg in HIV-Infected Subjects
- A 12-week Study to Compare the Efficacy and Safety of Fixed Combinations of Fenofibrate/Simvastatin 145/20mg and Fenofibrate/Simvastatin 145/40mg Tablets Versus Fenofibrate or Simvastatin Monotherapies in Subjects With Abnormal Blood Levels of Fats (Lipids) and at High Risk of Cardiovascular Disease
- A 16 Week Comparative Study of Fenofibrate Versus Ezetimibe as Add-on Therapy to Atorvastatin
Drugs (16)
- Atorvastatin HMG-CoA reductase inhibitor
- Atorvastatin calcium HMG-CoA reductase inhibitor
- Cerivastatin HMG-CoA reductase inhibitor
- Cerivastatin sodium HMG-CoA reductase inhibitor
- Fluvastatin HMG-CoA reductase inhibitor
- Fluvastatin sodium HMG-CoA reductase inhibitor
- Lovastatin HMG-CoA reductase inhibitor
- Pitavastatin HMG-CoA reductase inhibitor
- Pitavastatin calcium HMG-CoA reductase inhibitor
- Pitavastatin magnesium HMG-CoA reductase inhibitor
- Pitavastatin sodium HMG-CoA reductase inhibitor
- Pravastatin HMG-CoA reductase inhibitor
- Pravastatin sodium HMG-CoA reductase inhibitor
- Rosuvastatin HMG-CoA reductase inhibitor
- Rosuvastatin calcium HMG-CoA reductase inhibitor
- Simvastatin HMG-CoA reductase inhibitor